{"name":"Arbutus Biopharma Corporation","slug":"arbutus-biopharma-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARB-001467","genericName":"ARB-001467","slug":"arb-001467","indication":"Chronic hepatitis B","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TKM-080301","genericName":"TKM-080301","slug":"tkm-080301","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARB-001467","genericName":"ARB-001467","slug":"arb-001467","phase":"phase_2","mechanism":"ARB-001467 is an investigational drug that targets the hepatitis B virus.","indications":["Chronic hepatitis B"],"catalyst":""},{"name":"TKM-080301","genericName":"TKM-080301","slug":"tkm-080301","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBNY2trakplcWdlTGVYRmc3TjF6bjg3dTlGdGVJX0pFWG1Ea1pURW40NWtoV1FIUlVWcUdRTDh6YjZZVlluNFpPVk94dmVaS2FwWWJPb1RhRnJwREZsWHFEWHlaTjJlUTNCeWhZ?oc=5","date":"2026-03-09","type":"pipeline","source":"BUCKSCO.Today","summary":"Warminster-Founded Arbutus Biopharma to Receive $190M in Moderna Settlement - BUCKSCO.Today","headline":"Warminster-Founded Arbutus Biopharma to Receive $190M in Moderna Settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPLTBmaVJQRkZ6cVhtWXk0dko1T0VjNGYzZUQ0V2dBbVU0SHMxUmtCR1lqdVVqNW1La0xESGJnUjVNdnFOSWMwX1JTaWpXRDBaZWZWd2ROQXNnQnFWTFN2RVdWYVp1aURJM3RXUVhaVnNyQmItSzlFWlZmUXFXUmxGT190MUFxQjM5TmFMNmpoekxUaGFsV0NJVzNQRGpHWWNBT1E?oc=5","date":"2026-03-04","type":"pipeline","source":"Contract Pharma","summary":"Moderna Resolves Worldwide Arbutus/Genevant Litigation - Contract Pharma","headline":"Moderna Resolves Worldwide Arbutus/Genevant Litigation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQc2hiWUxnRVZ1SU8welFhZGYwUDgycDJpN1BnMnhwR20xWHZCR1loemZzVjRNdHJBVm1XMEFiY0JVemJRMldTTldUYnpydjA5Y3Z1cVpZOUhnS0xvak1iM28zZ28zQ3F3aEIzVzBwT3Y1RnAtWklLcFNHRERwNWlNYi14Z1ExaXB1UFRlcERlTndoeTIwSDAtV2ljaHhkNktoclFSMlR3XzV5eHlaX3U3TA?oc=5","date":"2026-03-03","type":"patent","source":"Stock Titan","summary":"Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan","headline":"Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZmk0ekItWl8xU2RrNENvU3gwNEI0eHN4d3dZRWlVTzBnXy1wNmZrQk5VOHZibzRuTE5GczA1TjhkMDIwQjA4TmRGQzlPMmxZWEs1cUZZUVNEcXo0bVkxd2RLWFM1aWxsaGxQMjNvRXVwY1lBUF9lNGlzaUREQlJYbHlOVjZZeEFTdENCWmh2dVhfeThZR3lvaC1BamMwcm5ENnZmX0NaUUVnLXM4aGZrRVFheEQzR3dHR0NLUlg4VkNXejc1ck9RUw?oc=5","date":"2026-03-03","type":"patent","source":"PharmaLive","summary":"Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive","headline":"Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5kWS00YTR6NVhwOUpPNE9CTnZXdDF2czJydEdNU1BfYW4wSkM5Q1hXaVlmV2tGejY0ZFpNTXc2RllUeG9OSm1oektPQzZTRzNwU2RRNnhaVzh1Mld1cjU4MzFZaVBaN2RsUTY0Vi1EODhIeHlOZEp0QjJhcE9BeXc?oc=5","date":"2026-02-05","type":"trial","source":"JD Supra","summary":"Judge Wolson Issues Key Summary Judgment Ruling on the Eve of Trial in the Arbutus v. Moderna mRNA Vaccine and Lipid Nanoparticle Case - JD Supra","headline":"Judge Wolson Issues Key Summary Judgment Ruling on the Eve of Trial in the Arbutus v. Moderna mRNA Vaccine and Lipid Nan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5MX1ZScjk3R3ZnUGVoZFR5QjBtN2MzMlhYQWlnUjJabTBpUXQ0Rzl4TDBsa2I1dURYS2xJM3NVWjFkN0ptbFBhdUpVOXVOdmNrLUlKbzk5ZkpXR2dGNFMxMU1sVjdVTGd6MGdPNjgtUm5teldONE4xSVVXOVNtNmM?oc=5","date":"2025-09-15","type":"pipeline","source":"Seeking Alpha","summary":"Arbutus: IP Drama With High Stakes (NASDAQ:ABUS) - Seeking Alpha","headline":"Arbutus: IP Drama With High Stakes (NASDAQ:ABUS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPbUppX01DWGsyTVlmQkgtdUU3aEpjT3FGaXpsRDhDTllCSnFtMU9DLUZDQVhQWGgzdUt1a0pTeEN6SkR4UkNoMF9GaXY3bnNVRDJ6QXhRVkI4bmRRZ1pLSGVPV2VtQWlQQ1VtV0IyU3NxOFRSX19lN3VFVFo5aGZCTnVxTFpFQjh3eE1mWg?oc=5","date":"2025-09-01","type":"pipeline","source":"Yahoo Finance","summary":"Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance","headline":"Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQN3F3dllraHpyenoyY0w0YXdBcXlMczNIaExkRDI0YUVRQ0ZxbVlkVlNVVVdhb3AyUjh0U0dtemItM09CSHlZUDlyWk51ejNHZ05vSGFTN01tSDFVLWFPR2NsME00YVRhN1hBOFdQQUJibWc3dUVDaGE5VjBmVUY2a2ZUaVJJbmVnTnZYa0xmaDNoS3M3UWNBQUU5YWhKWTNMT2xXdHVVTWs1TnJP?oc=5","date":"2025-06-25","type":"deal","source":"The Business Journals","summary":"Arbutus terminates potential $285M licensing deal with Chinese drug company - The Business Journals","headline":"Arbutus terminates potential $285M licensing deal with Chinese drug company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxObW44LXlJQ1MzLWJjeGRhQ25rVnRBMmp5T3lxUEFqY0IyTWViSkJ0NXNWbm9MT1VQcWFTcEp4V3NhVGlNNlAtNF9RT0pUZjYzZU9WclBRRDBpX0l0aGVHamJRT20wZWJ0ZDNIcF9BZ0dXYmtGOUVwb3JfTUJCWWFHREpwbDhjRlVaNlFYNGVWV2h0aEpvcThGQWQtc21FRTFKVE8tNGN5aHlWamJUbW5oa2JaTXF6VzhCRnJFdkZxYW5tUGEyOFpCQVRUZi11NmRUYzV1VDhSX24zRzBWcm56LXJzaVdBTGpzUmp0S3dHcGZnWEx5dXdXN1ZDTDFRa24yOXplM0xhZ19jTmVMNXpPY2tnTkRPbURXMnd2cmhSV0lyTDdfdWoyLQ?oc=5","date":"2025-06-25","type":"deal","source":"GlobeNewswire","summary":"Arbutus Reacquires Greater China Rights to Imdusiran and - GlobeNewswire","headline":"Arbutus Reacquires Greater China Rights to Imdusiran and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNREJ0NnlqUm1FUGZnNGFOV2g4ZXV6NTRDcTdlbDFRX0tZUGhsdmV1OURRYXIxVXhUYm9xdXEtZkpsT0tlRUxqb0VSV3hQOUdadFYwd0tOWk9QMnBBTVpxWWdVUTNjZFhpbTVUY3oybmdnQ1BKblFZb25scmg4TmtUTnhsN1JDVGNtdjBVclNoWQ?oc=5","date":"2025-03-27","type":"pipeline","source":"Fierce Biotech","summary":"Arbutus jettisons 57% of staff, ceases in-house research - Fierce Biotech","headline":"Arbutus jettisons 57% of staff, ceases in-house research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5GQnJyQW9RWUROeHpsMGpsUWZOUEtJQXFqbVd0X0FGQmpnQjJfZUxKUm8xRm5SOWVFaTk1a3ZrcFFoV2pVdGVHVmdZOHVuQWY4WFJN?oc=5","date":"2025-03-27","type":"pipeline","source":"FirstWord Pharma","summary":"Buckling down on HBV hopeful, Arbutus slashes more than half its workforce - FirstWord Pharma","headline":"Buckling down on HBV hopeful, Arbutus slashes more than half its workforce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNM3RuUHg1Yi1rRFFnRHhMUmcyaW5KSjNLSUJiYmJDQ3pJVzl2QXhuUTMwM1lUR3Iyb2ppRjBPam9nNk1xd3BhM21MUENIRjhMTEVncnFnZ1NIamRqS3VsakY4TkxYNmtabXRzR25NQ3Z0WDkyXzJiZUd0eWVTMTNwaG4zTFdkZXFLNDRhWUl4WDhUbDVGVEl0eGszTkdsOFhMR2JFTFN2NDdIdVdzc1BXRW1rMHBPMklwbWVR?oc=5","date":"2024-04-04","type":"patent","source":"Fierce Pharma","summary":"Arbutus, Genevant gain an edge in COVID patent scrap with Moderna - Fierce Pharma","headline":"Arbutus, Genevant gain an edge in COVID patent scrap with Moderna","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}